CN113082110A - 一种中药组合物的新用途 - Google Patents
一种中药组合物的新用途 Download PDFInfo
- Publication number
- CN113082110A CN113082110A CN202010020148.7A CN202010020148A CN113082110A CN 113082110 A CN113082110 A CN 113082110A CN 202010020148 A CN202010020148 A CN 202010020148A CN 113082110 A CN113082110 A CN 113082110A
- Authority
- CN
- China
- Prior art keywords
- parts
- tumor
- anemia
- traditional chinese
- chinese medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 48
- 239000000203 mixture Substances 0.000 title claims abstract description 31
- 208000007502 anemia Diseases 0.000 claims abstract description 59
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 55
- 238000011282 treatment Methods 0.000 claims abstract description 39
- 241000382455 Angelica sinensis Species 0.000 claims abstract description 22
- 244000303040 Glycyrrhiza glabra Species 0.000 claims abstract description 17
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 17
- 241000405414 Rehmannia Species 0.000 claims abstract description 16
- 238000002360 preparation method Methods 0.000 claims abstract description 16
- 241000007126 Codonopsis pilosula Species 0.000 claims abstract description 15
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims abstract description 14
- 235000006533 astragalus Nutrition 0.000 claims abstract description 10
- 241000112528 Ligusticum striatum Species 0.000 claims abstract description 9
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims abstract description 8
- 235000011477 liquorice Nutrition 0.000 claims abstract description 8
- 241000045403 Astragalus propinquus Species 0.000 claims abstract 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 34
- 235000001287 Guettarda speciosa Nutrition 0.000 claims description 29
- 239000008187 granular material Substances 0.000 claims description 27
- 244000236658 Paeonia lactiflora Species 0.000 claims description 14
- 235000008598 Paeonia lactiflora Nutrition 0.000 claims description 14
- 238000002512 chemotherapy Methods 0.000 claims description 13
- 238000002156 mixing Methods 0.000 claims description 12
- 235000017443 Hedysarum boreale Nutrition 0.000 claims description 9
- 235000007858 Hedysarum occidentale Nutrition 0.000 claims description 9
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 claims description 9
- 241001061264 Astragalus Species 0.000 claims description 8
- 238000001959 radiotherapy Methods 0.000 claims description 8
- 239000006228 supernatant Substances 0.000 claims description 8
- 239000003826 tablet Substances 0.000 claims description 8
- 210000004233 talus Anatomy 0.000 claims description 8
- 239000000341 volatile oil Substances 0.000 claims description 8
- 238000002560 therapeutic procedure Methods 0.000 claims description 7
- 239000002552 dosage form Substances 0.000 claims description 6
- 239000000284 extract Substances 0.000 claims description 5
- 239000012530 fluid Substances 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 5
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 4
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 4
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 4
- 201000004101 esophageal cancer Diseases 0.000 claims description 4
- 239000000706 filtrate Substances 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 4
- 206010017758 gastric cancer Diseases 0.000 claims description 4
- 201000007270 liver cancer Diseases 0.000 claims description 4
- 208000014018 liver neoplasm Diseases 0.000 claims description 4
- 201000005202 lung cancer Diseases 0.000 claims description 4
- 208000020816 lung neoplasm Diseases 0.000 claims description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 4
- 239000002674 ointment Substances 0.000 claims description 4
- 201000002528 pancreatic cancer Diseases 0.000 claims description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 4
- 238000007873 sieving Methods 0.000 claims description 4
- 238000005507 spraying Methods 0.000 claims description 4
- 238000003756 stirring Methods 0.000 claims description 4
- 201000011549 stomach cancer Diseases 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 208000036696 Microcytic anaemia Diseases 0.000 claims description 3
- 238000011127 radiochemotherapy Methods 0.000 claims description 3
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 208000028466 reproductive system neoplasm Diseases 0.000 claims description 2
- 241000125175 Angelica Species 0.000 claims 1
- 201000011453 reproductive organ cancer Diseases 0.000 claims 1
- MNQYNQBOVCBZIQ-JQOFMKNESA-A sucralfate Chemical compound O[Al](O)OS(=O)(=O)O[C@@H]1[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](COS(=O)(=O)O[Al](O)O)O[C@H]1O[C@@]1(COS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)O1 MNQYNQBOVCBZIQ-JQOFMKNESA-A 0.000 claims 1
- 229960004291 sucralfate Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 29
- 206010067484 Adverse reaction Diseases 0.000 abstract description 12
- 230000006838 adverse reaction Effects 0.000 abstract description 12
- 238000002474 experimental method Methods 0.000 abstract description 6
- 230000036737 immune function Effects 0.000 abstract description 6
- 230000001413 cellular effect Effects 0.000 abstract description 5
- 229940126680 traditional chinese medicines Drugs 0.000 abstract description 2
- 210000004369 blood Anatomy 0.000 description 51
- 239000008280 blood Substances 0.000 description 51
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 28
- 244000061520 Angelica archangelica Species 0.000 description 27
- 230000007812 deficiency Effects 0.000 description 15
- 210000003743 erythrocyte Anatomy 0.000 description 15
- 230000005906 menstruation Effects 0.000 description 15
- 230000001105 regulatory effect Effects 0.000 description 15
- 229910052742 iron Inorganic materials 0.000 description 14
- 238000000034 method Methods 0.000 description 12
- 239000002245 particle Substances 0.000 description 12
- 102100031939 Erythropoietin Human genes 0.000 description 10
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 10
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 10
- 238000005534 hematocrit Methods 0.000 description 10
- 108010092408 Eosinophil Peroxidase Proteins 0.000 description 9
- 241000700159 Rattus Species 0.000 description 9
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 9
- 229930006000 Sucrose Natural products 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 210000000952 spleen Anatomy 0.000 description 8
- 229960004793 sucrose Drugs 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 7
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 7
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 7
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 7
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 7
- 229940107666 astragalus root Drugs 0.000 description 7
- 229960004397 cyclophosphamide Drugs 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000002173 dizziness Diseases 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 239000005720 sucrose Substances 0.000 description 6
- 208000006083 Hypokinesia Diseases 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000000306 component Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 229940090044 injection Drugs 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 230000002093 peripheral effect Effects 0.000 description 4
- 208000000059 Dyspnea Diseases 0.000 description 3
- 206010013975 Dyspnoeas Diseases 0.000 description 3
- 102000001554 Hemoglobins Human genes 0.000 description 3
- 108010054147 Hemoglobins Proteins 0.000 description 3
- 102000008133 Iron-Binding Proteins Human genes 0.000 description 3
- 108010035210 Iron-Binding Proteins Proteins 0.000 description 3
- 229930192392 Mitomycin Natural products 0.000 description 3
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 3
- 206010033557 Palpitations Diseases 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 208000022400 anemia due to chronic disease Diseases 0.000 description 3
- 229940044683 chemotherapy drug Drugs 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000004821 distillation Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 229960004857 mitomycin Drugs 0.000 description 3
- 210000000581 natural killer T-cell Anatomy 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 3
- 208000013220 shortness of breath Diseases 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 208000030760 Anaemia of chronic disease Diseases 0.000 description 2
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 2
- 208000022531 anorexia Diseases 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 206010003549 asthenia Diseases 0.000 description 2
- 230000007969 cellular immunity Effects 0.000 description 2
- 230000003750 conditioning effect Effects 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 210000001508 eye Anatomy 0.000 description 2
- 239000011788 ferric saccharate Substances 0.000 description 2
- 235000008824 ferric saccharate Nutrition 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 229940097452 iron sucrose injection Drugs 0.000 description 2
- XRDYWGSODBNAIE-BQGRAUOOSA-K iron(3+);(2r,3s,4s,5s)-2,3,4,5,6-pentahydroxy-6-oxohexanoate Chemical compound [Fe+3].OC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O XRDYWGSODBNAIE-BQGRAUOOSA-K 0.000 description 2
- 238000009533 lab test Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 208000032467 Aplastic anaemia Diseases 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 240000001008 Dimocarpus longan Species 0.000 description 1
- 235000000235 Euphoria longan Nutrition 0.000 description 1
- 206010016880 Folate deficiency Diseases 0.000 description 1
- 208000010188 Folic Acid Deficiency Diseases 0.000 description 1
- 240000002045 Guettarda speciosa Species 0.000 description 1
- 208000018565 Hemochromatosis Diseases 0.000 description 1
- 208000031220 Hemophilia Diseases 0.000 description 1
- 208000009292 Hemophilia A Diseases 0.000 description 1
- 208000000616 Hemoptysis Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 101000987586 Homo sapiens Eosinophil peroxidase Proteins 0.000 description 1
- 101000920686 Homo sapiens Erythropoietin Proteins 0.000 description 1
- 239000009636 Huang Qi Substances 0.000 description 1
- 206010022971 Iron Deficiencies Diseases 0.000 description 1
- 208000015710 Iron-Deficiency Anemia Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 241000212322 Levisticum officinale Species 0.000 description 1
- 208000037093 Menstruation Disturbances Diseases 0.000 description 1
- 206010027339 Menstruation irregular Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 244000174681 Michelia champaca Species 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 235000006484 Paeonia officinalis Nutrition 0.000 description 1
- 241001106477 Paeoniaceae Species 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 206010067268 Post procedural infection Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 208000025371 Taste disease Diseases 0.000 description 1
- 206010043391 Thalassaemia beta Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 235000006545 Ziziphus mauritiana Nutrition 0.000 description 1
- 244000126002 Ziziphus vulgaris Species 0.000 description 1
- 235000008529 Ziziphus vulgaris Nutrition 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 239000002870 angiogenesis inducing agent Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 208000005980 beta thalassemia Diseases 0.000 description 1
- 208000015294 blood coagulation disease Diseases 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- FWZTTZUKDVJDCM-CEJAUHOTSA-M disodium;(2r,3r,4s,5s,6r)-2-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol;iron(3+);oxygen(2-);hydroxide;trihydrate Chemical compound O.O.O.[OH-].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[Na+].[Na+].[Fe+3].[Fe+3].[Fe+3].[Fe+3].[Fe+3].O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 FWZTTZUKDVJDCM-CEJAUHOTSA-M 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000010437 erythropoiesis Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000007475 hemolytic anemia Diseases 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 102000044890 human EPO Human genes 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000010832 independent-sample T-test Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229940082629 iron antianemic preparations Drugs 0.000 description 1
- 229940032961 iron sucrose Drugs 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 239000001645 levisticum officinale Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 235000019656 metallic taste Nutrition 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000001995 reticulocyte Anatomy 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 208000031162 sideroblastic anemia Diseases 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 208000035203 thalassemia minor Diseases 0.000 description 1
- 230000000287 tissue oxygenation Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 229940046001 vitamin b complex Drugs 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7016—Disaccharides, e.g. lactose, lactulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/236—Ligusticum (licorice-root)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/344—Codonopsis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/804—Rehmannia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种中药组合物在制备治疗肿瘤相关性贫血药物中的用途,属于中药领域。本发明所述的中药组合物主要由当归、熟地黄、川芎、白芍、黄芪、党参、甘草制备而成。经动物学及临床学实验证实,本发明中药组合物可以提高患者细胞免疫功能,对肿瘤相关性贫血有良好治疗作用,不良反应显著降低。
Description
技术领域
本发明涉及一种中药组合物的新用途,具体涉及一种中药组合物在制备治疗肿瘤相关性贫血药物中的用途,属于中药领域。
背景技术
肿瘤相关性贫血(CRA),又称癌性贫血,是指肿瘤本身或放疗、化疗等抗肿瘤治疗引起的贫血,是肿瘤常见的合并症之一,发病率可达39%~90%,尤其在接受放、化疗的肿瘤患者中,贫血的发生率可高达70%~90%,随着肿瘤研究的不断深入,CRA因其高发病率和不良影响越来越受到重视。
CRA可以引起很多临床症状,如疲劳、眩晕、心跳过速、认知缺损、气短等;同时CRA还会影响肿瘤治疗疗效。CRA发生时,贫血引起的组织氧合障碍可以刺激血管新生因子高表达,进而促进肿瘤的发生、发展以及转移,同时降低患者化疗敏感性,增加化疗后输血概率,损伤器官的功能,增加术后死亡率,最终降低患者生命质量和生存率。因此CRA是严重影响肿瘤患者生存期的因素,也是影响放化疗疗效的危险因素。
目前传统的CRA治疗方法有输血、促红细胞生成素EPO、补充铁剂等,输血治疗是目前临床上治疗CRA的主要方法,主要以全血输注或红细胞输注为主,但是由于输血本身存在风险,输血治疗缓解贫血症状的同时,也给患者带来了一定的风险,输血还可使自然杀伤细胞功能受抑,与肿瘤复发和术后感染的高风险相关;大量输血还可致血色病,而经济问题是限制输血治疗应用于CRA治疗的另外一个重要因素;
宋鑫等人报道了重组人促红细胞生成素联合铁剂应用于消化道肿瘤相关性贫血的研究,但是EPO治疗有一定适用范围,如无贫血的肿瘤患者和未进行化疗的患者不适用于这种治疗方法。同时EPO疗法也存在不足和不良反应。如EPO治疗起效慢,一般在用药2~3周后才起效,而且据调查有大约30%~50%的CRA患者对EPO治疗是没有反应的,限制EPO疗法使用的因素还有用药量大,价格贵。
铁剂补充也是CRA患者治疗贫血重要方法之一,在肿瘤患者中,特别是持续性接受过EPO治疗的大多数CRA患者最终都会发展成功能性的铁缺乏。这是因为储备于网状内皮系统中的铁在受到EPO刺激后而快速产生,在红细胞生成的过程中被大量地向骨髓转运并耗竭,而铁储备因为降低无法支持进一步的造血作用,因此影响了后续EPO治疗的效果,但是仅仅补充铁剂采用的是对症治疗,仅能暂时改善患者贫血的症状,但并不能完全从根本上治疗CRA。
中医学认为恶性肿瘤的发生、发展是内因、外因长期相互作用于人体的结果,本虚标实、虚实夹杂贯穿疾病的全过程,正气内虚、毒瘀并存是其病因病机。CRA属中医学“虚劳”、“血枯”、“血虚”等范畴,主要表现为乏力、头晕心悸、少气懒言、纳差等症。中医学认为CRA与五脏,尤其是脾、肾关系密切。脾为后天之本,精血的化生有赖于脾的运化。
中成方剂制剂当归调经颗粒和/或当归补血颗粒和/或当归补血颗粒,主要成分是当归、党参、黄芪、熟地、白芍、甘草,主要具有养血、补血、调经的功效。在临床应用中,主要对于身体患有气虚衰弱、身体产后血虚或者病后气血不足、月经不调、痛经的治疗都有良好的作用。因为对于身体出现的气血不足以及血瘀等症状,都可以通过此药物进行调理,有非常好的作用。能够改善身体出现急性失血引起的气血不足的表现。还能够增强身体的免疫机能,促进身体血小板凝聚作用。在临床应用中,对于身体出现的血瘀和血虚的症状,都有良好的调理和治疗作用。
黄志惠等人报道了加味当归补血汤与常规西药治疗肿瘤相关性贫血的临床对比研究结果,加味当归补血汤方剂组成为龙眼肉、补骨脂、白芍、熟地黄、鸡血藤、当归、大枣、黄芪、心慌明显加制远志,乏力气虚加人参,头晕明显加天麻。
因此,根据中医药的辩证论治,提供一种能明显改善肿瘤相关性贫血患者的临床症状,提高外周血红细胞计数及血红蛋白量,疗效确切明显,无明显毒副作用,价格低廉的中药组合物是一个亟需解决的问题。
发明内容
本发明发现了一种中药组合物的新用途,具体的涉及所述中药组合物在制备治疗肿瘤相关性贫血药物中的用途,治疗有效率高,疗效确切明显,无明显毒副作用,价格低廉。
本发明公开了一种中药组合物在制备治疗肿瘤相关性贫血药物中的用途,所述的中药组合物主要由当归、熟地黄、川芎、白芍、黄芪、党参、甘草制备而成。
优选的,所述中药组合物由以下组分制备而成:
当归50-500份 熟地黄5-100份 川芎2-30份
党参5-100份 白芍5-100份 甘草2-30份
黄芪5-100份;
进一步优选的,所述中药组合物由以下组分制备而成:
当归100-400份 熟地黄10-50份 川芎5-25份
党参10-50份 白芍10-50份 甘草5-25份
黄芪10-50份;
更优选的方案之一,所述中药组合物由以下组分制备而成:
当归150-300份 熟地黄15-30份 川芎8-15份
党参15-30份 白芍15-30份 甘草8-15份
黄芪15-30份;
更优选的方案之二,所述中药组合物由以下组分制备而成:
当归200份 熟地黄20份 川芎10份
党参20份 白芍20份 甘草10份
黄芪20份。
进一步地,本发明公开了上述中药组合物联合蔗糖铁剂在制备治疗肿瘤相关性贫血药物中的用途。
本发明所述的肿瘤相关性贫血,CRA属中医学“虚劳”、“血枯”、“血虚”等范畴,主要表现为乏力、头晕心悸、少气懒言、纳差等症。中医学认为CRA与五脏,尤其是脾、肾关系密切。脾为后天之本,精血的化生有赖于脾的运化;西医理论主要指肿瘤患者在其疾病的发展过程中以及治疗过程中发生的贫血,包括一些放化疗等抗肿瘤治疗引起的贫血。
本发明所述肿瘤相关性贫血为肿瘤本身引起的肿瘤相关性贫血和/或肿瘤治疗引起的肿瘤相关性贫血。
本发明所述肿瘤本身引起的相关性贫血的肿瘤包括但不限于肺癌、胃癌、结直肠癌、肝癌、食管癌、胰腺癌、生殖系统肿瘤、淋巴瘤。
本发明所述肿瘤本身引起的肿瘤相关性贫血为小细胞性贫血、正常细胞性贫血及大细胞性贫血。
优选的,所述小细胞性贫血是指缺铁性贫血、慢性疾病性贫血、轻型地中海贫血、铁粒幼红细胞性贫血及慢性疾病性贫血。
优选的,所述正常细胞性贫血是溶血性贫血、再生障碍性贫血及肾衰竭贫血。
优选的,所述大细胞性贫血是维生素B12缺乏性贫血、叶酸缺乏性贫血及骨髓细胞生成障碍综合征性贫血、慢性疾病性贫血。
本发明所述肿瘤治疗引起的肿瘤相关性贫血为放化疗引起的肿瘤相关性贫血。
优选的,所述放化疗引起的肿瘤相关性贫血的放化疗包括但不限于化疗放射性治疗、化疗药物性治疗。
中医辩证,CRA属于祖国医学的“血虚”、“血枯”、“虚劳”等的范畴中,多与气血不足、脾肾亏虚有关,以健脾补肾、益气养血为主要治疗原则。
本发明所述中药组合物可以制成任何一种药剂学上所说的剂型;优选的,所述剂型为颗粒剂、胶囊剂、丸剂、片剂、软膏剂中的一种或多种;进一步优选的,所述剂型为颗粒剂或软膏剂;进一步的,本发明所述的颗粒剂为当归调经颗粒和/或当归补血颗粒。
本发明还提供了上述当归调经颗粒和/或当归补血颗粒的制备方法,包括以下步骤:
(1)川芎、白芍用乙醇为溶剂进行渗漉,收集渗漉液;当归用蒸熘法提取挥发油,备用;
(2)将药渣与其余熟地黄等四味加水煎煮,合并煎滤,滤过,滤液浓缩,加五倍乙醇,搅匀,静置,取上清液备用;
(3)取步骤(2)的上清液与步骤(1)中渗漉液合并,回收乙醇,浓缩至清膏,备用;
(4)在步骤(3)的清膏中加入蔗糖及(或)乙醇适量,混匀,制成颗粒,干燥,过筛,喷加当归挥发油,分装,即得。
具体的,上述当归调经颗粒和/或当归补血颗粒的制备方法包括以下步骤:
(1)川芎用70%乙醇为溶剂、白芍用80%乙醇为溶剂进行渗漉,收集渗漉液;当归用蒸熘法提取挥发油,备用;
(2)将药渣与其余熟地黄等四味加水煎煮二次,合并煎滤,滤过,滤液浓缩至相对密度为1.15~1.18(50℃),加五倍70%乙醇,搅匀,静置,取上清液备用;
(3)取步骤(2)中的上清液与步骤(1)中渗漉液合并,回收乙醇,浓缩至相对密度为1.18~1.22(50℃)的清膏,备用;
(4)在步骤(3)的清膏中加入蔗糖及(或)乙醇适量,混匀,制成颗粒,干燥,过筛,喷加当归挥发油,制成1000g,分装,即得。
本发明有益效果体现为:
与单用蔗糖铁注射液、单用当归调经颗粒和/或当归补血颗粒的治疗方法相比,蔗糖铁注射液与当归调经颗粒和/或当归补血颗粒的联合治疗方法有效率提高23.0%(89.2%vs66.2%,P<0.05),提高Hb作用显著,患者Hb、RBC显著增高,RET明显较低,与其疗效较高相一致。组细胞免疫功能指标CD3+、CD4+、CD4+/CD8+、CD3-CD16+CD56+、CD3+CD16+CD56+显著增高,不良反应反生率相对下降15.4%(7.7%vs 23.1%,P<0.05)。表明当归补血颗粒可显著改善蔗糖铁引起的胃肠道、乏力等不适,提高生活质量,当归调经颗粒和/或当归补血颗粒可以提高患者细胞免疫功能,联合铁剂对肿瘤相关性贫血有良好治疗作用,且可降低铁剂引起的不良反应。
具体实施方式
一、具体实施例
实施例1:
处方为:
当归200g | 熟地黄20g | 川芎10g | 党参20g |
白芍20g | 甘草10g | 黄芪20g |
制备方法为:
(1)川芎用70%乙醇为溶剂、白芍用80%乙醇为溶剂进行渗漉,收集渗漉液;当归用蒸熘法提取挥发油,备用;
(2)将药渣与其余熟地黄等四味加水煎煮二次,合并煎滤,滤过,滤液浓缩至相对密度为1.15~1.18(50℃),加五倍70%乙醇,搅匀,静置,取上清液备用;
(3)取步骤(2)中的上清液与步骤(1)中渗漉液合并,回收乙醇,浓缩至相对密度为1.18~1.22(50℃)的清膏,备用;
(4)在步骤(3)的清膏中加入蔗糖及(或)乙醇适量,混匀,制成颗粒,干燥,过筛,喷加当归挥发油,制成1000g,分装,即得。
实施例2:
处方为:
当归50g | 熟地黄5g | 川芎2g | 党参5g |
白芍5g | 甘草2g | 黄芪5g |
制备方法:同实施例1。
实施例3:
处方为:
当归100g | 熟地黄10g | 川芎5g | 党参10g |
白芍10g | 甘草5g | 黄芪10g |
制备方法:同实施例1。
实施例4:
处方为:
当归150g | 熟地黄15g | 川芎8g | 党参15g |
白芍15g | 甘草8g | 黄芪15g |
制备方法为:同实施例1。
实施例5
处方为:
当归300g | 熟地黄30g | 川芎15g | 党参30g |
白芍30g | 甘草15g | 黄芪30g |
制备方法为:同实施例1所述制备方法。
实施例6:
处方为:
当归400g | 熟地黄50g | 川芎25g | 党参50g |
白芍50g | 甘草25g | 黄芪50g |
制备方法为:同实施例1。
实施例7:
处方为:
当归500g | 熟地黄100g | 川芎50g | 党参100g |
白芍100g | 甘草50g | 黄芪100g |
制备方法为:同实施例1。
二、动物学实验
以下仅以环磷酰胺、丝裂霉素两种化疗药物所致动物贫血模型为例说明本发明中药组合物对肿瘤相关性贫血的治疗效果,对于本发明中提到的其他类型或原因引起的肿瘤相关性贫血,发明人亦进行了相关的研究。研究结果表明,本发明中药组合物对其他类型或原因引起的肿瘤相关性贫血的治疗可以达到与以下动物实验类似或更优的效果。
(一)、本发明中药组合物对环磷酰胺、丝裂霉素两种化疗药物所致动物贫血模型的影响
1.实验动物
Wistar大白鼠,体重180~220g;昆明种小鼠,体重20~24g。由鲁南制药集团山东新时代药业有限公司药理中心提供,实验前适应性饲养一周。
2.实验用药物
实施例1所得当归调经颗粒和/或当归补血颗粒剂(规格:10g,鲁南厚普制药有限公司生产提供);环磷酰胺片(通化茂祥制药有限公司生产,批号:181101);丝裂霉素(日本协和发酵工业株式会社生产,批号:276ADC);蔗糖铁注射液(瑞士Vifor(International)Inc.生产,规格:5ml:100mg)。
3.造模
环磷酰胺致大鼠贫血模型建立
取健康大鼠40只,随机分4组,雌雄各半,每组10只,联合用药组给予0.5g/kg当归调经颗粒和/或当归补血颗粒剂+0.5g/kg蔗糖铁注射液,当归调经颗粒和/或当归补血颗粒剂组给予0.5g/kg当归调经颗粒和/或当归补血颗粒剂,蔗糖铁组给予0.5g/kg蔗糖铁注射液,正常组给予1mL/100g的自来水。每日上午分别给药,下午按70mg/kg喂饲环磷酰胺,连续10天,第12天大鼠右眼眼球取血,以CA600型血常规仪(日本Sysmex公司)测定Hb、红细胞(RBC)、红细胞比容(HCT),7170A型全自动生化分析仪(日本Hitachi公司)测定总铁结合力(TIBC)。
4.检测与结果
4.1检测:于给药第12天,各组随机选取8只处死,从大鼠的右眼眼球部位取血,以CA600型血常规仪(日本Sysmex公司)测定Hb、红细胞(RBC)、红细胞比容(HCT)、7170A型全自动生化分析仪(日本Hitachi公司)测定总铁结合力(TIBC)。
4.2结果
注:与正常组比较,*P<0.05,△P<0.01
结果见表1所示,颗粒剂组对对环磷酰胺造模大鼠外周血象的Hb、RBC、HCT、TIBC有提升作用,与正常组比较,*P<0.05,有显著差异性;联合用药组对环磷酰胺造模大鼠外周血象的Hb、RBC、HCT、TIBC均有明显的提升作用,与正常组比较,△P<0.01,有明显差异显著性。
三、临床学实验
2018年1月至2019年3月肿瘤科采用当归调经颗粒和/或当归补血颗粒联合铁剂治疗CRA,并观察对患者免疫功能的影响,结果满意,具体方法结果如下:
3.1资料与方法
3.1.1一般资料
选择收治的130例CRA患者按随机数字表法随机分为对照组65例和观察组65例,
对照组:男36例,女29例,年龄(60.2±7.7)岁;原发病:肺癌21例,胃癌14例,结直肠癌9例,肝癌8例,食管癌、胰腺癌各4例,其它5例;治疗方式:化疗20例,手术14例,手术+化疗31例;贫血程度(轻度:男性血红蛋白(Hb)浓度90~120g/L,女性90~110g/L;中度:患者Hb浓度60~90g/L;重度:患者Hb浓度30~60g/L;极重度:患者Hb浓度<30g/L。):轻度7例,中度27例,重度31例。
观察组:男40例,女25例,年龄(59.1±11.6)岁;原发病:肺癌19例,胃癌15例,肝癌10例,结直肠癌6例,食管癌4例,胰腺癌3例,其它8例;贫血程度(轻度:男性血红蛋白(Hb)浓度90~120g/L,女性90~110g/L;中度:患者Hb浓度60~90g/L;重度:患者Hb浓度30~60g/L;极重度:患者Hb浓度<30g/L。):轻度9例,中度22例,重度34例。经统计,两组患者年龄、性别、健康状况等其他临床资料间无显著性差异(P>0.05)。
3.1.2纳入标准
细胞学或病理学确诊为恶性肿瘤;KPS评分≥60分,预计生存期>6个月;患者知情同意。
3.1.3排除标准
极重度贫血;原发性血液系统疾病如血友病等引起的贫血;凝血功能障碍;近1个月有输血史,EPO或糖皮质激素使用史;罹患的恶性肿瘤侵犯血管引起咯血、便宜血等大出血;心肝肾等脏器功能严重障碍;过敏体质等。
3.1.4治疗方法
对照组:蔗糖铁注射液(瑞士Vifor(International)Inc.生产,规格:5ml:100mg)加入生理盐水中静滴,2支/次,3次/周;口服叶酸片(北京斯利安药业有限公司生产,规格:10mg),1片/次,3次/d;复合维生素B片(广东恒健制药有限公司生产,规格:复方),2片/次,3次/d。治疗期间依据检测血常规情况,Hb≤30g/L时,予以成分输血;Hb:30~60g/L者,酌情输血。测得Hb升至120g/L时停药。
观察组:在对照组的基础上加用当归调经颗粒和/或当归补血颗粒(规格:10g,鲁南厚普制药有限公司生产),1袋/次,3次/d。8周为一疗程,测得Hb升至120g/L时停药。
3.1.5观察指标
①实验室检查:CA600型血常规仪(日本Sysmex公司)测定Hb、红细胞(RBC)、红细胞比容(HCT)、网织红细胞百分比(RET),7170A型全自动生化分析仪(日本Hitachi公司)测定总铁结合力(TIBC)。
②细胞免疫功能测定:抽取外周静脉血上流式细胞仪(FACS Calibur,美国BD公司)检测,记录CD3+、CD4+、CD8+、CD16+CD56+、CD3+CD16+CD56+亚群表达百分率,并计算CD4+/CD8+。其中,CD3+为T淋巴细胞总值,CD19+为B细胞亚群,CD16+CD56+为自然杀伤(NK)细胞,CD3+CD16+CD56+为自然杀伤T细胞(NKT细胞)。
③记录不良反应。
3.1.6疗效评价标准
以治疗后Hb为依据,Hb≥120g/L或升高≥20g/L为显效;Hb升高≥10g/L、但<20g/L为有效;未达上述标准者为无效。总有效率=显效率+有效率。
3.1.7统计方法
采用SPSS 22.0软件包进行处理,计数资料用χ2检验;计量资料组间比较采用独立样本t检验,不符合正态分布者采用秩和检验,组内治疗前后自身比较采用配对t检验,用t检验,P<0.05为差异有统计学意义。
3.2结果
3.2.1两组临床疗效比较
所有患者均完成8周的治疗。经统计,对照组显效11例,有效22例,无效22例,总有效率为66.2%;观察组显效20例,有效38例,无效7例,总有效率为89.2%,观察组较高(P<0.05)。
3.2.2两组实验室检查结果比较
治疗前,两组患者Hb、RBC、HCT、RET和TIBC均无统计学差异(P>0.05)。治疗后,两组Hb、RBC、HCT显著增高,RET、TIBC显著下降;组间比较,观察组Hb、RBC明显较高,RET明显较低(P<0.05)。
注:与治疗前相比*P<0.05;与对照组比较,△P<0.05
3.2.3两组外周血淋巴细胞亚群比较
治疗前,两组患者外周血淋巴细胞亚群均无统计学差异(P>0.05)。治疗后,对照组各指标也无统计学改变;观察组CD8+和CD19+无统计学改变,CD3+、CD4+、CD4+/CD8+、CD3-CD16+CD56+、CD3+CD16+CD56+显著增高(P<0.05);与对照组相比均有显著性差异(P<0.05)。
注:与治疗前相比*P<0.05;与对照组比较,△P<0.05
3.2.4两组不良反应率比较
对照组出现头晕头痛4例,恶心呕吐、金属味3例,血压降低、乏力2例,瘙痒1例,不良反应发生率为23.1%(15/65);观察组头晕头痛、金属味各2例,不良反应发生率为7.7%(4/65),观察组不良反应发生率较低(P<0.05)。
据以上结果表明,与单用蔗糖铁的对照组相比,加用当归调经颗粒和/或当归补血颗粒的观察组临床有效率提高23.0%(89.2%vs 66.2%,P<0.05),表明其提高Hb作用显著。实验室检查示该组患者Hb、RBC显著增高,RET明显较低,与其疗效较高相一致。肿瘤免疫主要以T淋巴细胞为基础,细胞免疫、体液免疫共同参与机体抗肿瘤的过程,本研究显示,治疗后观察组细胞免疫功能指标CD3+、CD4+、CD4+/CD8+、CD3-CD16+CD56+、CD3+CD16+CD56+显著增高,即T淋巴细胞、NK细胞、NKT细胞功能均明显提高,这也可能是其作用机制之一。观察组不良反应反生率较对照组下降15.4%(7.7%vs 23.1%,P<0.05),表明当归调经颗粒和/或当归补血颗粒可显著改善蔗糖铁引起的胃肠道、乏力等不适,提高生活质量。
综上所述,当归调经颗粒和/或当归补血颗粒可以提高患者细胞免疫功能,联合铁剂对肿瘤相关性贫血有良好治疗作用,且可降低铁剂引起的不良反应。
Claims (10)
1.一种中药组合物在制备治疗肿瘤相关性贫血药物中的用途,所述的中药组合物主要由当归、熟地黄、川芎、白芍、黄芪、党参、甘草制备而成。
2.如权利要求1所述的用途,其特征在于,所述中药组合物由以下组分制备而成:
当归50-500份 熟地黄5-100份 川芎2-30份
党参5-100份 白芍5-100份 甘草2-30份
黄芪5-100份;
优选地,所述中药组合物由以下组分制备而成:
当归150-300份 熟地黄15-30份 川芎8-15份
党参15-30份 白芍15-30份 甘草8-15份
黄芪15-30份;
优选地,所述中药组合物由以下组分制备而成:
当归200份 熟地黄20份 川芎10份
党参20份 白芍20份 甘草10份
黄芪20份。
3.如权利要求2所述的用途,其特征在于,所述中药组合物可以制成任何一种药剂学上的剂型;优选的,所述剂型为颗粒剂、胶囊剂、丸剂、片剂、软膏剂中的任意一种;进一步优选的,所述剂型为颗粒剂或软膏剂。
4.如权利要求1所述的用途,其特征在于,所述肿瘤相关性贫血为肿瘤本身引起的肿瘤相关性贫血和/或肿瘤治疗引起的肿瘤相关性贫血。
5.如权利要求4所述的用途,其特征在于,所述肿瘤本身引起的相关性贫血的肿瘤,包括但不限于肺癌、胃癌、结直肠癌、肝癌、食管癌、胰腺癌、生殖系统肿瘤、淋巴瘤。
6.如权利要求4所述的用途,其特征在于,所述肿瘤本身引起的相关性贫血,包括但不限于小细胞性贫血,正常细胞性贫血及大细胞性贫血。
7.如权利要求4所述的用途,其特征在于,所述肿瘤治疗引起的肿瘤相关性贫血为放化疗引起的肿瘤相关性贫血。
8.如权利要求7所述的用途,其特征在于,所述放化疗引起的肿瘤相关性贫血的放化疗包括但不限于化疗放射性治疗,化疗药物性治疗。
9.如权利要求1-8任一项所述的用途,其特征在于,所述中药组合物的制备方法为:
(1)川芎、白芍用乙醇进行渗漉,收集渗漉液;当归提取挥发油,备用;
(2)将药渣与其余熟地黄等四味加水煎煮二次,合并煎滤,滤过,滤液浓缩,加乙醇,搅匀,静置,取上清液备用;
(3)取步骤(2)中的上清液与步骤(1)中渗漉液合并,回收乙醇,浓缩得清膏,备用;
(4)在步骤(3)的清膏中加入辅料适量,混匀,制成颗粒,干燥,过筛,喷加当归挥发油,分装,即得。
10.如权利要求1所述的用途,其特征在于,所述中药组合物联合蔗糖铁剂用于制备治疗肿瘤相关性贫血药物。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010020148.7A CN113082110A (zh) | 2020-01-09 | 2020-01-09 | 一种中药组合物的新用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010020148.7A CN113082110A (zh) | 2020-01-09 | 2020-01-09 | 一种中药组合物的新用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113082110A true CN113082110A (zh) | 2021-07-09 |
Family
ID=76663690
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010020148.7A Pending CN113082110A (zh) | 2020-01-09 | 2020-01-09 | 一种中药组合物的新用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113082110A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116870067A (zh) * | 2023-08-10 | 2023-10-13 | 上海纳米技术及应用国家工程研究中心有限公司 | 一种缓解vb12吸收障碍的中药组合物及其制备方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1785220A (zh) * | 2005-12-09 | 2006-06-14 | 贵州益佰制药股份有限公司 | 补血当归制剂的质量控制方法 |
CN108498631A (zh) * | 2018-06-23 | 2018-09-07 | 贵州威门药业股份有限公司 | 无糖型当归调经颗粒及其制备方法 |
-
2020
- 2020-01-09 CN CN202010020148.7A patent/CN113082110A/zh active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1785220A (zh) * | 2005-12-09 | 2006-06-14 | 贵州益佰制药股份有限公司 | 补血当归制剂的质量控制方法 |
CN108498631A (zh) * | 2018-06-23 | 2018-09-07 | 贵州威门药业股份有限公司 | 无糖型当归调经颗粒及其制备方法 |
Non-Patent Citations (2)
Title |
---|
乔小燕;杨树明;蔡焦生;: "圣愈汤治疗恶性肿瘤化疗后贫血的临床观察", 光明中医, vol. 25, no. 08, pages 1 - 3 * |
杨培民等: "《中西医结合肿瘤治疗学》", 30 November 2014, 山东科学技术出版社, pages: 323 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116870067A (zh) * | 2023-08-10 | 2023-10-13 | 上海纳米技术及应用国家工程研究中心有限公司 | 一种缓解vb12吸收障碍的中药组合物及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100548323C (zh) | 一种由绞股蓝、西洋参和黄芪制成的药物组合物 | |
CN103041312B (zh) | 具有抗肿瘤作用的中药组合物及其制备方法和应用 | |
CN112972547B (zh) | 一种治疗气血两虚症候的中药组合物及其制备方法和应用 | |
CN102302608B (zh) | 一种治疗贫血的中药组合物及其制备方法 | |
CN113082110A (zh) | 一种中药组合物的新用途 | |
CN111905051A (zh) | 具有防治慢性心衰气阴两虚血瘀水停证作用的中药组合物及其制备方法与应用 | |
CN114558074B (zh) | 一种具有治疗代谢相关脂肪性肝病的中药组合物及其制备方法与应用 | |
CN107961272B (zh) | 一种用于慢性肾脏病的中药组合物 | |
CN105147996B (zh) | 一种补肾益髓生血方及其膏剂和颗粒的制备方法 | |
CN111544528B (zh) | 一种治疗原发性干燥综合征的中药组合物及其应用 | |
CN102258626B (zh) | 中药复方藤黄霖、其制备方法及其应用 | |
CN102755445A (zh) | 一种用于治疗白细胞减少症的中药制剂及其制备工艺 | |
CN112717097A (zh) | 一种治疗胃癌的中药组合物及其制备方法 | |
TW202206090A (zh) | 黃耆醫藥組合物用於增強癌症治療之用途 | |
CN101642485B (zh) | 一种含黄芪的药物组合物在制备治疗白细胞减少症、过敏性紫癜症的药物中的应用 | |
CN110613792A (zh) | 一种具有降血糖作用的中药组合物及其制备方法和应用 | |
CN100352471C (zh) | 治疗继发性贫血、缺铁性贫血的药物及其制备方法 | |
CN112206298A (zh) | 一种中药组合物在制备治疗腹泻药物中的应用 | |
CN110075234A (zh) | 一种抗肿瘤中药组合物 | |
CN116920047B (zh) | 一种新型冠状病毒感染相关心肌损伤的中药复方组合物及制备方法 | |
CN113101330B (zh) | 一种调经组合物及其应用 | |
CN114796417B (zh) | 一种降血糖中药组方及其制备方法 | |
CN117899159A (zh) | 一种治疗化疗后骨髓抑制的药物及其制作方法 | |
CN117244016A (zh) | 一种防治癌因性疲乏的中药组合物及制备方法 | |
CN107213323B (zh) | 一种滋阴化痰、散结解毒的中药复方制剂及其用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |